Sitemap
Pages
- Email Disclaimer
- Sitemap
- Strategic Update 5
- Disclaimer
- Thank You
- Privacy Policy
- HCP
- Investors – Duplicate – Analyst – Update
- Xeroderma Pigmentosum (XP)
- Cosmetics
- Frankfurt Rendez-Vous 2023 Factsheet
- Arterial Ischaemic Stroke (AIS)
- Welcome to CLINUVEL
- RISK MANAGEMENT AND ESG STATEMENT
- Disease Entities
- Healthcare Solutions
- CLINUVEL CUVIP Jaap van Zweden sign up
- Clinuvel Pharmaceuticals Monaco Soirée
- Investor Relations Contact Form
- Strategic Update II – About
- Pharmaceutical Technology
- Clinuvel Pharmaceuticals Factsheet 2022
- Strategic Update II – Home
- Contact
- Clinuvel Pharmaceuticals US Factsheet 2022
- CLINUVEL CUVIP Cristina Ramos sign up
- SCENESSE
- Strategic Update II – R&D
- Strategic Update II – A Sixth Indication
- CLINUVEL Financial Strength
- Stroke Q&A
- Strategic Update II – DNA Repair Program
- Erythropoietic Protoporphyria (EPP)
- New York Rendez-vous RSVP
- Frankfurt Rendez-Vous 2023 Thank you
- Healthcare Professional
- New York Rendez-Vous 2023 Factsheet
- Investors
- CLINUVEL Value Building
- News
- Strategic Update II – CNS Program
- ASX Announcements
- Strategic Update II – Healthcare Solutions
- CLINUVEL Ambassadors sign up
- Strategic Update II – Communications, Branding and Marketing
- Strategic Update II – Manufacturing
- Variegate Porphyria (VP)
- Strategic Update 3
- Strategic Update II – We Are CLINUVEL
- Vitiligo
- Strategic Update 4
- About CLINUVEL
- Cookie Details
- People
- DNA Repair
- Strategic Update II – Strategy and Planning – DNA Program
- Strategic Update II – Further Clinical Use of Afamelanotide
- FAQ
- Strategic Update 6
Posts
- Appendix 3Y – Change of Director’s Interest Notice
- CEO letter to shareholders
- CLINUVEL Confirms AGM Date
- CLINUVEL Vitiligo Expert Panel
- SCENESSE® in adolescent EPP study
- Investor Webinar transcript
- Appendix 4G and Corporate Governance Statement
- CLINUVEL delivering on a long-term strategy with increase in annual revenues, profit
- Dividend/Distribution – CUV
- Appendix 4E & Annual Report
- Annual Results – Investor Webinar
- Technical Note: DNA Damage and Repair
- Afamelanotide Significantly Reduces DNA Damage in a Healthy Population
- SCENESSE® applied under five-year Veterans Affairs contract
- CLINUVEL secures IP for melanocortins to treat central nervous system disorders
- Notification regarding unquoted securities
- Two grounds of Appeal upheld by NICE Panel
- News Kommuniqué III
- Notification of cessation of securities
- Twilight Event – Briefing
- Change of Director’s Interest Notice
- News Communiqué III
- Strategic Update VI
- CLINUVEL Bulletin Edition 01
- CLINUVEL escalates PRÉNUMBRA® to moderate/severe stroke patients
- Expansion of CLINUVEL’s global porphyria programs
- News Kommuniqué II
- News Communiqué I – Ms Cristina Ramos
- News Communiqué II
- Investor Presentation – NYC Nasdaq Event
- First stroke patient treated with PRÉNUMBRA® Instant
- Technical note: Arterial Ischaemic Stroke (AIS)
- DNA Repair data presented at American Academy of Dermatology Meeting
- Statement on Silicon Valley Bank (SVB)
- Proposed issue of Securities
- News Communiqué I – Maestro Jaap van Zweden
- Commercial Update SCENESSE®
- Relief from Quarterly Reporting
- CLINUVEL launches CYACÊLLE, Next Generation Solar Care
- CYACÊLLE Polychromatic Solar Care – λ3
- Proposed issue of Securities
- Global SCENESSE® demand drives increased CLINUVEL revenues, earnings
- Appendix 4D Half Yearly Report
- PRÉNUMBRA® Formulation Completed For Clinical Trial Use
- Chair’s Letter
- Afamelanotide Significantly Reduces UV Skin Damage in a Healthy Population – Technical Note
- CLINUVEL Drug Significantly Reduces Critical UV Skin Damage in Fair-Skinned Individuals
- Afamelanotide Significantly Reduces UV Skin Damage in a Healthy Population
- Appendix 4C & Activity Report
- Technical Note: Developing a melanocortin pipeline
- NEURACTHEL® manufacturing processes advance
- Media release: CLINUVEL Trial Results Show Drug Reduces DNA Damage
- Afamelanotide Reduces DNA Photodamage in Xeroderma Pigmentosum – Technical Note
- Afamelanotide Reduces DNA Photodamage in Xeroderma Pigmentosum
- News Kommuniqué 1
- News Communiqué I
- CLINUVEL Communiqué VI
- Notification of cessation of securities
- Jefferies London Healthcare Conference
- CLINUVEL Communiqué V
- Appendix 3Y – Change of Director’s Interest Notice
- Appendix 4C & Activity Report
- Chair’s Address
- Results of Annual General Meeting 2022
- CLINUVEL Pharmaceuticals Investor Briefing Melbourne
- First vitiligo patient enrolled in afamelanotide monotherapy study
- CLINUVEL’s Sydney Soirée 2022
- CLINUVEL PHARMACEUTICALS LTD Annual General Meeting – Notice of Meeting & Explanatory Memorandum 2022
- Strategic Update V
- H.C. Wainwright 24th Annual Global Investment Conference
- CLINUVEL confirms AGM date
- CLINUVEL submits SCENESSE® label expansion for adolescent EPP patients
- CLINUVEL Kommuniqué IV
- CLINUVEL Investor Webinar Financial Results Year Ended 30 June 2022
- Appendix 4G
- Revenue Growth Drives CLINUVEL’s Sixth Consecutive Annual Profit
- Dividend/Distribution – CUV
- Appendix 4E & Annual Report
- CLINUVEL Communiqué IV
- Chair’s Letter
- PRÉNUMBRA® for stroke
- Appendix 4C & Activity Report
- CLINUVEL Kommuniqué III
- Change of Director’s Interest Notice
- CLINUVEL Communiqué III
- Change of Director’s Interest Notice
- Notice of ceasing to be a substantial holder
- Jeffries Healthcare Conference June 2022
- H.C. Wainwright Global Investment Conference 2022
- Notice of change of interests of initial substantial holder
- Notice of initial substantial holder
- Strategic Update IV
- Change of Director’s Interest Notice
- CLINUVEL progresses vitiligo treatment program
- CLINUVEL progresses vitiligo study
- Notification regarding unquoted securities
- Positive final results in stroke
- CEO letter
- Appendix 4C & Activity Report
- Notice of ceasing to be a substantial holder
- CLINUVEL Kommuniqué II
- Initial Director’s Interest Notice
- Chair’s Letter
- CLINUVEL appoints new Non-Executive Director
- CLINUVEL Extends Employment Agreement With CEO
- DNA Repair Communiqué II
- CLINUVEL Communiqué II
- First XP-V Patient Treated in CLINUVEL DNA Repair Study
- Change of Director’s Interest Notice
- ACTH Manufacturing Update
- Afamelanotide in stroke (AIS) – positive preliminary results
- Change of Director’s Interest Notice
- CEO letter
- CLINUVEL Reports Record December Half Year Operating Profit
- Appendix 4D – ASX Listing Rule 4.2A.3 Half Yearly Report
- Financial Results Half Year Ended, 31 December 2021
- DNA Repair Communiqué I
- CLINUVEL Expands DNA Repair Program with 2nd DNA Repair Study
- Appendix 4C & Activity Report
- CLINUVEL Kommuniqué 1
- CLINUVEL Communiqué 1
- SCENESSE® continued in Germany
- Change of Director’s Interest Notice
- Notification of Cessation of Securities
- CLINUVEL completes enrolment in world-first stroke study
- CLINUVEL’S GROWTH AND EXPANSION – H.C. Wainwright Bioconnect Conference 2022
- Progress of CLINUVEL’s DNA Repair Program
- Chair’s Letter to Shareholders
- CLINUVEL Kommuniqué VI
- SCENESSE® as Vitiligo Monotherapy
- Vitiligo Communiqué IV
- CLINUVEL Communiqué VI
- CLINUVEL Kommuniqué V
- CLINUVEL Communiqué V
- In memory of David Blake – London, 18 November 2021
- CLINUVEL’S GROWTH AND EXPANSION – Jefferies London Healthcare Conference
- Results of Annual General Meeting 2021
- Chair Address
- CEO’s Address – 2021 Annual General Meeting
- CLINUVEL Expands Pharmaceutical Portfolio
- Strategic Update III
- Response to Price Query
- CLINUVEL Adds ACTH to Portfolio
- Appendix 4C & Activity Report
- CLINUVEL Investor Webinar Released
- First Patient Treated in CLINUVEL DNA Repair Study
- CLINUVEL Investor webinar
- Appendix 4G & Corporate Governance Statement
- CLINUVEL PHARMACEUTICALS LTD 2021 Annual General Meeting – Notice of Meeting & Explanatory Memorandum
- Operations Update II
- Operations Update Webcast II
- CLINUVEL Progresses DNA Repair Program
- CLINUVEL Key Events and Announcements
- CLINUVEL Confirms AGM Date
- Notification regarding unquoted securities – CUV
- Presentation H.C. Wainwright Global Investment Conference
- CLINUVEL Kommuniqué IV
- CLINUVEL Investor Webinar Financial Results Year Ended 30 June 2021
- CLINUVEL Communiqué IV
- Corporate Presentation – FY2021 Results
- Appendix 4E and Preliminary Financial Report
- CLINUVEL Delivers Record Revenues and Profit
- Dividend/Distribution – CUV
- SCIENTIFIC COMMUNIQUÉ XI: Developing Novel Treatments for Arterial Ischaemic Stroke Patients
- Afamelanotide well tolerated by first stroke patients
- Appendix 4C & Activity Report
- Insider Insights III: Willem Blijdorp – Challenges & the Future
- Insider Insights II: Willem Blijdorp – CLINUVEL’s Products, People & Social Purpose
- Appendix 3Y Change of Director’s Interest Notice
- Insider Insights: Willem Blijdorp – Chair of The CLINUVEL Group
- Appendix 3Y Change of Director’s Interest Notice
- CLINUVEL Kommuniqué III
- Media Release – First stroke patient treated with afamelanotide
- First stroke patient treated with afamelanotide
- CLINUVEL Presentation to Jefferies Healthcare Conference
- CLINUVEL Communiqué III
- Appendix 3Y Change of Director’s Interest Notice
- Chairman’s Letter II
- SCIENTIFIC COMMUNIQUÉ X: Photoprotection and the significance of Minimal Erythema Dose (MED) testing
- Appendix 4C & Activity Report
- Wilsons Initiates Research Coverage of CLINUVEL
- CLINUVEL Strategic Update II
- CLINUVEL Kommuniqué II
- CLINUVEL Communiqué II
- Chair’s Letter I
- Media Release – CLINUVEL Expands DNA Repair Program
- SCENESSE® To Be Evaluated in Xeroderma Pigmentosum Variant (XPV)
- Investor Presentation – Daiwa Investment Conference Tokyo 2021
- Appendix 3Y Change of Director’s Interest Notice
- Appendix 3Y Change of Director’s Interest Notice
- SCIENTIFIC COMMUNIQUÉ IX
- Operations Update Webinar
- CLINUVEL Reports Tenth Consecutive Half Year Net Profit
- Appendix 4D Half Year Report
- Financial Results Half Year Ended 31 December 2020
- SCENESSE® Granted Market Access In Israel
- Kommuniqué I
- Appendix 4C & Activity Report
- Position vacant: Web Developer
- Position vacant: Copywriter
- CLINUVEL Communiqué I
- H.C. Wainwright Bioconnect Conference 2021
- Appendix 3G
- Change in substantial holding
- CLINUVEL Newsletter VI
- SCIENTIFIC COMMUNIQUÉ VIII
- SCENESSE® DNA REPAIR STUDY IN HEALTHY VOLUNTEERS APPROVED
- SCIENTIFIC COMMUNIQUÉ VII
- Jefferies Virtual London Healthcare Conference Presentation
- Chair’s Letter To Shareholders
- Commsec Executive Series interview with Dr Philippe Wolgen
- Annual General Meeting Webcast
- Results of Annual General Meeting
- MANAGING DIRECTOR’S PRESENTATION TO CLINUVEL ANNUAL GENERAL MEETING
- CHAIR’S ADDRESS TO CLINUVEL ANNUAL GENERAL MEETING
- CLINUVEL Strategic Update – Extended
- APPENDIX 4C AND ACTIVITY REPORT
- CLINUVEL Strategic Update – Executive Summary
- Afamelanotide for Acute Stroke Patients
- Media Release – CLINUVEL to Trial Innovative Drug in Stroke
- Media Release – TGA approves Australian drug to protect patients from light and sun
- Australian TGA approves SCENESSE®
- Update: SCENESSE® in DNA Repair
- CLINUVEL Pharmaceuticals Limited (ASX: CUV) – Trading Halt
- CLINUVEL AGM Shareholder Question Form
- Further Research Coverage Initiated on CLINUVEL
- Presentation – Value in the Vines Investor Conference
- Appendix 4G and Corporate Governance Statement
- CLINUVEL Annual General Meeting 2020
- CLINUVEL Annual Report 2020
- SCIENTIFIC COMMUNIQUÉ VI
- CLINUVEL News & Facts site live
- Kommuniqué V, 20-23 September 2020
- CLINUVEL Newsletter V
- CLINUVEL CONFIRMS AGM DATE
- Change of Director’s Interest Notice
- Media Release – First patient dosed in SCENESSE® DNA Repair Program
- First patient dosed in SCENESSE® DNA Repair Program
- Media Release (ASX) – CLINUVEL progresses innovative DNA Repair Program
- Media Release – New drug to repair damaged skin and reduce skin cancer risk
- SCENESSE® in DNA Repair
- Change of Director’s Interest Notice – Appendix 3Y
- Proposed issue of Securities
- Opening of VALLAURIX R&D facilities in Singapore
- Media Release – CLINUVEL opens VALLAURIX R&D centre in Singapore
- Corporate Presentation – 2020 Full Year Results
- CLINUVEL Declares Full Year Dividend
- CLINUVEL Full Year Results 2020
- CLINUVEL Webinar – Preliminary Financial Results
- Appendix 4E and Preliminary Financial Report 2020
- CLINUVEL Corporate Update
- Appendix 4C – quarterly
- Kommuniqué IV
- CLINUVEL Newsletter
- Media Release – Second Afamelanotide Formulation
- PRÉNUMBRA® – New Liquid Afamelanotide Presentation
- Lapse and Forfeit of Unlisted Conditional Performance Rights
- Presentation Jefferies Global Healthcare Conference
- Appendix 3B and Appendix 3Y Withdrawn
- CLINUVEL Expands Singapore Laboratories
- Request for FDA Guidance Meeting SCENESSE® in Vitiligo
- Australian TGA commences SCENESSE® review
- Appendix 4C
- CLINUVEL Kommuniqué I
- CLINUVEL Newsletter
- SCENESSE® registration dossier submitted in Australia
- Notice of Change of Interests of Substantial Holder
- Change of Director’s Interest Notice
- Lapse and Forfeit of Unlisted Conditional Performance Rights
- Changes of Director’s Interest Notice
- Appendix 3B
- Changes in Composition to Committeess
- CEO Letter
- Appendix 3X
- CLINUVEL Appoints Non-Executive Director
- Chair’s Address to the Annual General Meeting
- Results of Meeting
- Managing Director’s AGM Presentation
- Appendix 4C
- TGA Priority Registration Pathway for SCENESSE
- Letter from the Remuneration Committee Chair
- CLINUVEL Chair to Retire Following FDA Approval
- Appendix 4G and Corporate Governance Statement
- Annual Report to shareholders
- Notice of Annual General Meeting/Proxy Form
- CLINUVEL Newsletter
- Chair Letter to Shareholders
- Audio Transcript Investor Teleconference
- FDA Grants Marketing Approval For SCENESSE
- Trading Halt
- CLINUVEL Renews Employment Agreement With CEO
- FDA Clarifies SCENESSE® PDUFA Date
- CLINUVEL Confirms AGM Date
- Appendix 3X
- CLINUVEL Appoints New Director
- SCENESSE® presented at ICPP in Milan
- Appendix 3Y
- CLINUVEL Notification of Dividend/Distribution
- CLINUVEL Clarifies ex-Dividend Date
- CLINUVEL Declares Final Dividend
- Appendix 4E and Preliminary Financial Report
- CLINUVEL program discussed at Light and Life 2019 Conference
- CLINUVEL Newsletter – August 2019
- Appendix 4C
- Change in Composition of Audit & Risk Committee
- CLINUVEL Newsletter – July 2019
- CLINUVEL Relocates Melbourne Office
- CLINUVEL INCLUDED IN S&P/ASX 200 INDEX
- Presentation Jefferies Healthcare Conference
- Lapse and forfeit of Unlisted Conditional Performance Rights
- Media Release – US FDA review for SCENESSE® extended 3 months
- US FDA extends PDUFA date for SCENESSE®
- Change of Director’s Interest Notice
- Becoming a substantial holder
- CLINUVEL Newsletter
- Appendix 4C
- Chair Letter to Shareholders
- Presentation Goldman Sachs Emerging Leaders Conference
- CLINUVEL Hosts European EPP Clinical Expert Meetings
- CLINUVEL Newsletter – March 2019
- UK NICE Meeting Held
- Change in substantial holding
- Change in substantial holding
- Change of Director’s Interest Notice x 3
- Appendix 3B
- Investor Briefing
- Appendix 4D Half Yearly Report
- CLINUVEL Vitiligo Communiqué II
- CLINUVEL Newsletter – February 2019
- Appendix 4C
- Change of Director’s Interest Notice
- CLINUVEL Newsletter – January 2019
- US FDA sets PDUFA date for SCENESSE®
- CLINUVEL Vitiligo Communiqué
- CUV103 Singaporean Phase II vitiligo study results
- CLINUVEL Newsletter – December 2018
- Results of Meeting
- Managing Director AGM Presentation
- Chair’s Address to the Annual General Meeting
- CLINUVEL Newsletter – November 2018
- Appendix 4C
- CLINUVEL expands Singapore laboratory facilities
- Appendix 4G and Corporate Governance Statement
- Notice of Annual General Meeting/Proxy Form
- Appeal Upheld Against NICE Recommendation in England
- Sachs 18th Biotech in Europe Forum Presentation
- Chair Letter to Shareholders
- Ceasing to be a substantial holder
- CLINUVEL Confirms AGM Date
- CLINUVEL Initiates Variegate Porphyria Proof of Concept Study
- Nasdaq International Designation Virtual Investor Conference Presentation
- Appendix 3B
- Investor Presentation NewsMakers Conference
- US FDA Update
- Change in substantial holding
- Notification of dividend / distribution
- CLINUVEL declares first time dividend
- Appendix 4E and Preliminary Financial Report
- CLINUVEL Investor Summary
- Appendix 4C
- CLINUVEL Newsletter – July 2018
- Change in substantial holding
- Change in Director’s Interest Notice
- Change in substantial holding
- CLINUVEL COMPLETES SCENESSE® FDA FILING
- Trading Halt
- Appendix 3B
- NICE MAINTAINS ITS POSITION NOT TO RECOMMEND SCENESSE® FOR REIMBURSEMENT
- Change in substantial holding
- Change in substantial holding
- CLINUVEL REGULATORY UPDATE
- Change in substantial holding
- CLINUVEL TO TAKE 100% OWNERSHIP OF VALLAURIX
- Appendix 4C
- CLINUVEL Newsletter – March 2018
- CLINUVEL HOLDS EUROPEAN ERYTHROPOIETIC PROTOPORPHYRIA (EPP) EXPERT MEETING
- CLINUVEL sustains profitability first-half of year
- CLINUVEL unveils new global positioning
- CLINUVEL Newsletter – February 2018
- Appendix 3X – Karen Agersborg
- Appendix 4C
- CLINUVEL appoints US based Director
- Chair Letter to Shareholders
- Preliminary recommendation by NICE not to include SCENESSE® for reimbursement by NHS England
- CLINUVEL Newsletter – December 2017
- Lapse and Forfeit of Unlisted Conditional Performance Rights
- Appendix 3Z – Final Director’s Interest Notice
- Managing Director’s AGM Presentation
- Results of Meeting
- Chair’s Address to the Annual General Meeting
- Response to ASX Price Query
- Appendix 4C
- Notice of Annual General Meeting/Proxy Form
- Appendix 4G
- CLINUVEL Newsletter – October 2017
- CLINUVEL CONFIRMS AGM DATE
- ELIE ISHAG TO RETIRE FROM CLINUVEL BOARD
- CLINUVEL PROVIDES UPDATE ON SCENESSE® FDA FILING
- Appendix 3B
- Appendix 4E – Preliminary Final Report 2016/17
- Notice of change of interests of a substantial holder
- Appendix 4C – Quarterly report
- CLINUVEL Newsletter – July 2017
- Appendix 3B
- CLINUVEL Newsletter – May 2017
- NICE ENGLAND UPDATE ON SCENESSE®
- Appendix 4C – Quarterly report
- Lapse and Forfeit of Unlisted Conditional Performance Rights
- CLINUVEL reaches agreement on German SCENESSE® pricing through AMNOG Arbitration Board
- Appendix 4D and Half Year Report
- CLINUVEL Newsletter – February 2017
- Appendix 4C – Quarterly report
- Appendix 3Y
- CLINUVEL Newsletter – December 2016
- Appendix 3Y
- Results of Meeting
- Chair’s Address to the Annual General Meeting
- Managing Director’s AGM Presentation
- CLINUVEL agrees with FDA on New Drug Application timelines
- Response to Price Query
- Appendix 4C
- Notice of Annual General Meeting/Proxy Form
- Appendix 4G
- CLINUVEL relocates Melbourne office
- FDA erythropoietic protoporphyria (EPP) scientific workshop
- SCENESSE® NICE ENGLAND UPDATE
- FDA SCHEDULES PRE-NDA MEETING FOR SCENESSE®
- Media release: FDA, CLINUVEL TO DISCUSS SCENESSE® AT PRE-NDA MEETING
- CLINUVEL Confirms Date of Annual General Meeting
- Chair’s Letter
- Appendix 4E – Preliminary Final Report 2015/16
- Lapse and Forfeit of Unlisted Conditional Performance Rights
- CLINUVEL Newsletter – August 2016
- Notice of Initial Substantial Holder
- Appendix 3Y
- Appendix 3B
- CLINUVEL completes pre-clinical study of SCENESSE® as combination therapy
- Appendix 4C – Q4 FY16
- FDA accepts SCENESSE® clinical data package for NDA submission
- FDA awards SCENESSE® Fast Track designation for treatment of EPP
- CLINUVEL’s SCENESSE® launched in Europe
- CLINUVEL added to Nasdaq International Designation
- SCENESSE® treatment in Europe
- Appendix 4C – Q3 FY16
- Form 604
- CLINUVEL Newsletter – April 2016
- NICE Highly Specialised Technology workshop reviews SCENESSE®
- s.708A Notice
- Appendix 3B
- Form 604
- Form 604 – March 15, 2016
- CLINUVEL accredits first European EPP expert centres
- CLINUVEL placement of A$8.3 million completed successfully
- Request for Trading Halt
- Appendix 4D and Half Year Report
- CLINUVEL brief on European commercialisation
- SCENESSE® receives US FDA orphan designation for cutaneous porphyrias
- Presentation to international porphyria patient group
- Appendix 4C – Q2 FY16
- Form 604
- CEO Brief – January 20, 2016
- Form 604